Literature DB >> 20823827

[S100B protein and autoantibodies to S100B protein in diagnostics of brain damage in craniocerebral trauma in children].

E G Sorokina, Zh B Semenova, O K Granstrem, O V Karaseva, S V Meshcheriakov, V P Reutov, G N Sushkevich, V G Pinelis, L M Roshal'.   

Abstract

Levels of antibodies AB (AB) to S100B and S100B protein were studied in the blood serum of children with different severity and outcomes of traumatic brain injury (TBI) from the 1st to 15-75th days after TBI. Severity and outcomes were assessed using the Glasgow Coma Scale (GCS). Patients were stratified by outcomes into the following groups: complete recovery (group 1), moderate disability (group 2), high disability (group 3), vegetative state (group 4) and fatal outcome (group 5). In patients of groups 1-3, the changes of S100B in the blood serum didn't depend on the severity of brain's damage; the significant increase of S100B protein levels in the 1st day was accompanied by the decrease to the normal range in the following 2-3 days. On the contrary, the levels of nAB in these groups increased starting from 3-5 days corresponding to the severity of brain's damage. The development of vegetative state was accompanied by low S100B and high AB to S100B levels in the blood serum. The maximal level of S100B protein and increased levels of AB were observed in patients with fatal outcome. In most patients with combined TBI, the levels of both parameters were higher compared to those with separate TBI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823827

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  5 in total

1.  Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study.

Authors:  Kevin K W Wang; Zhihui Yang; John K Yue; Zhiqun Zhang; Ethan A Winkler; Ava M Puccio; Ramon Diaz-Arrastia; Hester F Lingsma; Esther L Yuh; Pratik Mukherjee; Alex B Valadka; Wayne A Gordon; David O Okonkwo; Geoffrey T Manley; Shelly R Cooper; Kristen Dams-O'Connor; Allison J Hricik; Tomoo Inoue; Andrew I R Maas; David K Menon; David M Schnyer; Tuhin K Sinha; Mary J Vassar
Journal:  J Neurotrauma       Date:  2016-02-01       Impact factor: 5.269

2.  Is peripheral immunity regulated by blood-brain barrier permeability changes?

Authors:  Erin Bargerstock; Vikram Puvenna; Philip Iffland; Tatiana Falcone; Mohammad Hossain; Stephen Vetter; Shumei Man; Leah Dickstein; Nicola Marchi; Chaitali Ghosh; Juliana Carvalho-Tavares; Damir Janigro
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

3.  Consequences of repeated blood-brain barrier disruption in football players.

Authors:  Nicola Marchi; Jeffrey J Bazarian; Vikram Puvenna; Mattia Janigro; Chaitali Ghosh; Jianhui Zhong; Tong Zhu; Eric Blackman; Desiree Stewart; Jasmina Ellis; Robert Butler; Damir Janigro
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

4.  Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products.

Authors:  Zhiqun Zhang; J Susie Zoltewicz; Stefania Mondello; Kimberly J Newsom; Zhihui Yang; Boxuan Yang; Firas Kobeissy; Joy Guingab; Olena Glushakova; Steven Robicsek; Shelley Heaton; Andras Buki; Julia Hannay; Mark S Gold; Richard Rubenstein; Xi-Chun May Lu; Jitendra R Dave; Kara Schmid; Frank Tortella; Claudia S Robertson; Kevin K W Wang
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

5.  Antibody profiling identifies novel antigenic targets in spinal cord injury patients.

Authors:  Ilse Palmers; Elke Ydens; Eric Put; Bart Depreitere; Helma Bongers-Janssen; Peter Pickkers; Sven Hendrix; Veerle Somers
Journal:  J Neuroinflammation       Date:  2016-09-13       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.